- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05473962
Mid-Term Follow-up Assessment After Exposure to Natural Disaster (MFAE-ND)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Description: Assessment 24 months after exposure to a natural disaster of the clinical condition of children and adolescents cared for by medical-psychological emergency teams (CUMP) by measuring the frequency of clinical disorders and the intensity of symptoms and by comparing their clinical condition to that assessed immediately after exposure.
- Primary endpoint:
Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the assessment and quantification of symptoms related to post-traumatic stress. This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
- Secondary endpoints:
- The intensity of the symptoms of this PTSD will be assessed by the Young Child PTSD checklist (YCPC) (Scheeringa, 2013; translation of the French version: Thümmler et al., 2017) for young children under the age of 7. For children over 7 years of age, it will be assessed by the Child PTSD checklist, child version (CPC) (Scheeringa, 2014; translation and validation of the French version: Gindt et al., 2020).
- Patient Health Questionnaire 13 items (PQH13). This simple and quick to use instrument allows a systematic assessment of somatization in children. This questionnaire will be offered to parents of children under 7 years of age as a hetero-assessment and directly to children over 7 years of age as a selfassessment.
- Parental Stress Index - Short Form (PSI-SF): Short version of the Parental Stress Index. The instrument will be offered to parents of study participants in self-report. It evaluates the magnitude of stress in the parent-child system.
Interventions :
The study has two phases:
The clinician-led interview will be conducted with the parent(s) or directly with the child in a face-to-face or remote setting.
-The scales will be validated via an online platform. An initial analysis of the general data (primary and secondary criteria) will be carried out using various descriptive statistics indicators. Depending on the participation rate in the study and the total number of participants, a general linear model analysis will be performed on the different indicators collected (presence/absence of the different symptoms, and scores on the different instruments) in order to describe the evolution of the children's symptoms. The data collected in this study will then be compared to the initial post-exposure assessment.
Duration: The estimated duration of the study is one year (including analyses). Participation in the inclusion period is six months. The duration of participation per person in the study will be 30 minutes of interview + 20 minutes of delivery of psychological instruments.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nice, France
- Hôpitaux Pédiatriques de Nice CHU-Lenval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Child and/or young adult aged under 18 at the time of exposure having been assessed by the CUMPS teams during the "ALEX Storm" interventions of October 2020
- Affiliated to a social security scheme
- Children whose parents have accepted participation in the study and/or young adults who have accepted participation in the study (collection of non-objection
Exclusion Criteria:
- Children and/or young adults with a severe somatic and/or psychiatric disorder that makes assessment impossible or may alter emotional regulation behavior.
- Non-participation in a parallel study that could modify emotional regulation behavior
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
exposed to Alex storm
Child and/or young adult aged under 18 at the time of exposure having been assessed by the CUMPS teams during the "ALEX Storm" interventions of October 2020
|
Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5.
This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method).
The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diagnostic criteria for post-traumatic stress disorder
Time Frame: at inclusion
|
Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD). This tool as 517 items. This scale doesn't work on numerical values (there is no min, max or cut scores), this scale makes it possible to confirm or invalidate the presence of symptoms necessary for establishing diagnoses on Diagnosis and Statistical Manual of Mental Disorders (DSMV) criteria |
at inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intensity of the symptoms
Time Frame: at inclusion
|
The intensity of the symptoms of this PTSD will be assessed by the Young Child PTSD checklist (YCPC) for young children under the age of 7. For children over 7 years of age, it will be assessed by the Child PTSD checklist, child version (CPC) These scales aim to screen for post-traumatic stress disorder symptoms in children aged 1 to 6 years old, by evaluating traumatic exposures (13 items), symptoms presented by the child (23 items) and his level of impairment or functional impairment (6 items). Items 14 to 36 relate to symptoms of PTSD and are based on a 5-points Likert scale, each item is scored from 0 to 4, the YCPC has a score ranging from 0 to 92. The diagnosis Cutoff is at 26 or more for items 14-36, it indicates a "probable diagnosis" of PTSD. |
at inclusion
|
|
assessment of somatization
Time Frame: at inclusion
|
Patient Health Questionnaire 13 items (PQH13). This simple and quick to use instrument allows a systematic assessment of somatization in children. This questionnaire will be offered to parents of children under 7 years of age as a hetero-assessment and directly to children over 7 years of age as a selfassessment Thirteen items, each of which is scored 0 to 2, providing a 0 to 30 severity score. |
at inclusion
|
|
Parental Stress
Time Frame: at inclusion
|
Parental Stress Index - Short Form (PSI-SF): Short version of the Parental Stress Index. The instrument will be offered to parents of study participants in self-report. It evaluates the magnitude of stress in the parent-child system The "Parental Stress Index Short Form" is a self-assessment intended for the child's parent The PSI-SF has 36 items from the original 120-item PSI and based on a 5-points Likert scale, each item is scored from 1 to 5, the PSI-SF has a score ranging from 36 to 180. Percentile scores are used to interpret the scores. Scores at or above the 85th percentile are considered high (normal range : 15th-80th percentile |
at inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-HPNCL-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychiatric Disorder
-
Stéphane MorandiUniversity of LausanneNot yet recruitingPsychiatric Disorder | Involuntary Psychiatric HospitalizationSwitzerland
-
Mental Health Services in the Capital Region, DenmarkUniversity of CopenhagenRecruitingMental Illness | Behavior Disorders | Psychiatric Disorder | Mental Disorder | Severe Mental Disorder | Psychiatric Illness | Diagnosis, Psychiatric | Psychiatric Disease | Diagnosis DualDenmark
-
Medical University InnsbruckActive, not recruiting
-
Massachusetts General HospitalTerminatedObsessive-Compulsive Disorder | Pediatric Psychiatric DisorderUnited States
-
Michael RuferUniversity of ZurichEnrolling by invitationHealth Care Utilization | Chronic Psychiatric Disorder | Psychiatric Hospitalization | Intensive Care Psychiatric Disorder | Rehospitalization | High Utilization / Heavy UseSwitzerland
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Brigham and Women's HospitalActive, not recruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
Roswell Park Cancer InstituteRecruitingPsychiatric DisorderUnited States
-
Stanford UniversityRecruiting
-
University of SalzburgEnrolling by invitationMental Illness | Psychiatric Disorder | Mental DisorderAustria
Clinical Trials on assessment and quantification of symptoms related to post-traumatic stress.
-
Hospices Civils de LyonCompletedPregnancy Related | Cytomegalovirus Infections | MothersFrance
-
Federal University of Rio Grande do SulHospital de Clinicas de Porto Alegre; Conselho Nacional de Desenvolvimento... and other collaboratorsCompletedCOVID-19 | SARS-CoV-2 InfectionBrazil
-
Parc de Salut MarRecruitingPost-traumatic Stress Disorder | Psychological TraumaSpain
-
Dr. Behcet Uz Children's HospitalCompleted
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.Not yet recruitingPost-traumatic Stress SymptomsUnited States
-
Institut Paoli-CalmettesCompleted
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Assistance Publique Hopitaux De Marseille; F-CRIN INNOVTE Research NetworkRecruiting
-
Direction Centrale du Service de Santé des ArméesInstitut de Recherche Biomedicale des ArmeesCompleted
-
Direction Centrale du Service de Santé des ArméesActive, not recruitingCovid19 | Burnout, Professional | SARS-CoV Infection | Burnout, CaregiverFrance
-
Hospital Sao DomingosNot yet recruitingCOVID-19 Post-Intensive Care Syndrome